In the phase II study among 32 patients with germline BRCA1/2 mutant platinum-sensitive ovarian cancer, disease control rate at 12 weeks and ORR were 81% and 63%, respectively [48]. This evidence concerns the gene BRCA1 and ovarian cancer.